Dr. Suckow is also a Research Scientist, New York State Psychiatric Institute, New York, NY and Associate Research Scientist, Dept. of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, NY. He obtained his B.S. in Pharmacy from Columbia University, College of Pharmacy; his M.S. in Toxicology from St. John’s University, College of Pharmacy; and his Ph.D. in Pharmacology, also from St. John’s University. Previously, he was a research associate, Research Foundation for Mental Hygiene, Rockland Research Institute, Orangeburg, NY, and a licensed pharmacist in the states of New York and New Jersey.
- Rho Chi National Pharmaceutical Honor Society
- European Patent Office: Patent No. EP1644005B1, Metabolite of Quetiapine; Inventors: Scott W. Grimm, Helen R. Winter, Patricia C. Davis, Raymond F. Suckow, Jeffrey Goldstein; Assignee: AstraZeneca AB; Date of Issue: July 16, 2010
- Chinese Patent Office: Patent No. CN1816339B, Metabolite of Quetiapine; Inventors: Jeffrey Goldstein, Scott W. Grimm, Helen R. Winter, Patricia C. Davis, Raymond F. Suckow; Assignee: AstraZeneca AB; Date of Issue: December 15, 2010
Suckow RF, Zhang MF, Cooper TB, Enantiomeric determination of the phenylmorpholinol metabolite of bupropion in human plasma using coupled achiral-chiral liquid chromatography, Biomed. Chromatogr., 11, 174-179 (1997).
Suckow RF, Fein M, Correll CU, Cooper TB, Determination of plasma ziprasidone using liquid chromatography with fluorescence detection, J. Chromatogr., 799, 201-208 (2004).
Serebruany VL, Suckow RF, Cooper TB, O’Connor CM, Malinin AI, Krishnan KRR, van Zyl LT, Lekht V, Glassman AH, SADHART, Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N- desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression, Am. J. Psychiatry, 162, 1165-1170 (2005).
Slifstein M, Suckow RF, Javitch JA, Cooper TB, Lieberman JA, Abi-Dargham A, Characterization of in vivo pharmacokinetic properties of the dopamine D1 receptor agonist DAR-0100A in nonhuman primates using PET with [11C] NNC 112 and [11C] raclopride, J. Cereb. Blood Flow Metab., 31, 293-304 (2011).
Lopez LV, Shaikh A, Merson J, Greenberg J, Suckow RF, Kane JM, Accuracy of clinician assessments of medication status in the emergency setting: a comparison of clinician assessment of antipsychotic usage and plasma level determination, J. Clin. Psychopharmacol., 37(3), 310-314 (2017).